Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313534 · ClinicalTrials.gov registry record · Phase 1
Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer
A Phase 1 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00313534 is a Phase 1 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 15 participants.
The verdict
NCT00313534, a Phase 1 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.
Interventions
- DRUG masoprocol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00313534
The ClinicalTrials.gov registry entry for NCT00313534 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which masoprocol is the first listed.
NCT00313534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00313534 about?
NCT00313534 is a clinical study titled "Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer". RATIONALE: Nordihydroguaiaretic acid may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nordihydroguaiaretic acid in treating patients with nonmetastatic relapsed prostate cancer.
What is the current status of trial NCT00313534?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2005-06. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00313534?
The interventions under investigation include: masoprocol (DRUG).
Who is sponsoring clinical trial NCT00313534?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.